Cover Image
市場調查報告書

全球癌症診斷檢驗市場

Cancer Diagnostic Testing World Markets

出版商 TriMark Publications 商品編碼 203885
出版日期 內容資訊 英文 264 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症診斷檢驗市場 Cancer Diagnostic Testing World Markets
出版日期: 2016年01月01日 內容資訊: 英文 264 Pages
簡介

癌症檢查領域在今後3∼5年之間將成為最重要的成長領域之1。根據National Cancer Institute的預測,約1,000萬的美國人罹患某種癌症。製藥公司針對癌症正在開發的藥劑有300種以上,但部分在開發中,並有超過500項持續中的研究開發計劃。

本報告提供腫瘤標記(癌症篩檢)檢查裝置市場概要,提供您美國及全球銷售趨勢,市場規模,以及參與企業簡介,課題,新技術領域和今後預測等資訊。

第1章 概要

第2章 癌症的生物學和診斷產業概要

  • 癌症
    • 疾病
    • 轉移
    • 癌症的人口統計和統計學
  • 生物科技和診斷產業的促進要素
    • 技術創新
    • 政府的資金援助
  • 腫瘤標記(癌症篩檢)的展望

第3章 腫瘤標記(癌症篩檢)市場區隔分析:規模,成長,及佔有率

  • 市場概要
  • 臨床診斷用血清腫瘤標記(癌症篩檢)
  • PSA 檢驗市場規模
  • DNA 標記
  • 血清蛋白質
  • 酵素
  • 潛血
  • 組織學和In Situ的混合化
  • 子宮頸細胞診斷
  • 免疫細胞化學
  • 體內癌症檢驗用產品
  • 放射性核素與X光掃描檢驗產品
  • HPV檢驗
  • 膀胱癌檢驗
  • 輔助化療的腫瘤檢驗

第4章 癌症發現的診斷方法

  • 各種器官的腫瘤標記(癌症篩檢)
  • 腫瘤標記(癌症篩檢)測量的臨床檢驗手法
  • 癌症診斷的新技術

第5章 有新技術平台的癌症診斷市場參與企業

第6章 癌症診斷檢驗產業的商務趨勢

  • 產業的整合化
  • 各種產品和價格設定
  • 醫療設備相關政府法規
  • 腫瘤標記(癌症篩檢)的商機
  • 癌細胞成長抑制劑
  • 生物產業趨勢
  • 製藥產業趨勢
  • 腫瘤標記(癌症篩檢)檢驗銷售,行銷策略
  • 診斷企業的M&A

第7章 基礎研究能放的新的癌症市場

  • 癌症的遺傳性特徵
  • DNA錯配修復基因 (MMRs)
  • Telomeres(染色體末端部位)
  • 癌症的種類
  • 腫瘤標記(癌症篩檢)
  • 技術
  • 不同疾病技術
  • 超高感度癌症診察
  • 反轉錄酶聚合酵素鏈鎖反應(RT-PCR)
  • 遺傳性癌症的風險遺傳基因檢驗
  • 潛在的新標記之技術性及實用上的課題
  • 遺傳基因分析
  • 倍數性
  • 全世界的醫療支出額

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: TMRCDTWM16-1101

Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this TriMark Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.

Table of Contents

1. Overview

  • 1.1 Statement of Report
  • 1.2 About This Report
  • 1.3 Scope of the Report
  • 1.4 Objectives
  • 1.5 Methodology
  • 1.6 Executive Summary

2. Introduction to Cancer Biology and the Diagnostic Industry

  • 2.1 Cancer
    • 2.1.1 The Disease
    • 2.1.2 Metastasis
    • 2.1.3 Demographics and Statistics of Cancer
  • 2.2 The Drivers of the Biotech and Diagnostics Industry
    • 2.2.1 Technological Innovation
    • 2.2.2 Government Funding
  • 2.3 Outlook for Tumor Markers

3. Tumor Markers Market Segment Analysis: Size, Growth and Share

  • 3.1 Market Description
  • 3.2 Clinical Diagnostic Serum-based Cancer Markers
  • 3.3 PSA Testing Market Size
  • 3.4 DNA Markers
  • 3.5 Serum Proteins
  • 3.6 Enzymes
  • 3.7 Occult Blood
  • 3.8 Histology and In Situ Hybridization (ISH)
  • 3.9 Cervical Cytology
  • 3.10 Immunohistochemistry (IHC)
  • 3.11 In Vivo Detection Cancer Products
  • 3.12 Radionuclides and X-Ray Detection Products
  • 3.13 HPV Testing
  • 3.14 Bladder Cancer Testing
  • 3.15 Tumor Assays for Adjuvant Chemotherapy

4. Diagnostic Methods for Cancer Detection

  • 4.1 Organ-Specific Tumor Markers
    • 4.1.1 Colon Cancer
    • 4.1.2 Prostate Cancer
    • 4.1.3 Pancreatic Cancer
    • 4.1.4 Breast Cancer
    • 4.1.5 Ovarian Cancer
    • 4.1.6 Cervical Cancer
    • 4.1.7 Lung Cancer
    • 4.1.8 Testicular Cancer
    • 4.1.9 Bladder Cancer
    • 4.1.10 Hepatic Cancer
    • 4.1.11 Stomach Cancer
    • 4.1.12 Malignant Melanoma
    • 4.1.13 Acute Myeloid Leukemia (AML) and Acute Lymphoblastoid Leukemia (ALL)
    • 4.1.14 Lymphoma
  • 4.2 Clinical Laboratory Methods for Measuring Tumor Markers
    • 4.2.1 Abbott Diagnostics
    • 4.2.2 Roche Diagnostics Systems
    • 4.2.3 Beckman Coulter Diagnostics Immunoassay Systems
    • 4.2.4 Siemens Healthcare Diagnostics ADVIA Centaur CP Immunoassay System, the ADVIA Centaur XP Immunoassay System and ADVIA Centuar XPT Immunoassay System
    • 4.2.5 Tosoh Bioscience AIA-2000
    • 4.2.6 Thermo Fisher Scientific B.R.A.H.M.S. KRYPTOR
    • 4.2.7 Ortho-Clinical Diagnostics Vitros ECiQ (Johnson and Johnson)
    • 4.2.8 Fujirebio Diagnostics, Inc.
    • 4.2.9 bioMérieux Vidas
  • 4.3 New Technologies for Cancer Diagnostics
    • 4.3.1 New and Improved Immunoassays
    • 4.3.2 IHC Tests
    • 4.3.3 Molecular (DNA and Genomic) Diagnostic Assays
    • 4.3.4 Genomics and Genetic Markers
    • 4.3.5 Proteomics and New Protein Markers
    • 4.3.5.1 Inside the ProteinChip System
    • 4.3.5.2 Rapid Biological Assays on a Chip
    • 4.3.5.3 Proteome Pattern Recognition
    • 4.3.6 New Platform Technologies Including Flow Cytometry
    • 4.3.7 Stem Cell Markers
    • 4.3.8 mAbs
    • 4.3.9 Pharmacogenomics and Oncology Diagnostics
    • 4.3.10 DNA Microarrays
    • 4.3.11 In Vitro Diagnostic Multivariate Index Assays (IVDMIA)
    • 4.3.12 Prostate-63
    • 4.3.13 Future Directions

5. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms

  • 5.1 Abbott Diagnostics
  • 5.2 Agendia BV
  • 5.3 bioMérieux
  • 5.4 DRG International, Inc.
  • 5.5 Eisai Co., Ltd.
  • 5.6 Exact Sciences Corporation
  • 5.7 Fujirebio Diagnostics, Inc.
  • 5.8 Genomic Health, Inc.
  • 5.9 Hologic, Inc.
  • 5.10 LabCorp
  • 5.11 Myriad Genetics, Inc.
  • 5.12 Neogenomics
  • 5.13 Roche
  • 5.14 Siemens
  • 5.15 Tosoh Corporation (Bioscience Division)

6. Business Trends in the Industry

  • 6.1 Industry Consolidation
  • 6.2 Breadth of Product Offering and Pricing
  • 6.3 Government Regulation of Medical Devices
  • 6.4 Commercial Opportunities in Cancer Markers
  • 6.5 Moderators of Growth
  • 6.6 Biotechnology Industry Trends
  • 6.7 Pharmaceutical Industry Trends
  • 6.8 Sales and Marketing Strategies for Tumor Marker Tests
    • 6.8.1 North American Market
    • 6.8.2 International Markets
      • 6.8.2.1 Europe
      • 6.8.2.2 Central and South America
      • 6.8.2.3 Asia-Pacific
  • 6.9 Mergers and Acquisitions (M&As) of Diagnostic Companies

7. New Cancer Markers in Basic Research

  • 7.1 Genetics of Cancer
    • 7.1.1 Activator Genes (Oncogenes)
    • 7.1.2 Inactivating Genes (Tumor Suppressor Genes)
  • 7.2 DNA Mismatch Repair Genes (MMRs)
  • 7.3 Telomeres
  • 7.4 Diseases
    • 7.4.1 t(15;17) in Acute Promyelocytic Leukemia (APL)
    • 7.4.2 t(12;21) in Acute Lymphoblastic Leukemia (ALL)
    • 7.4.3 Retinoblastoma and Constitutional 13q14 Deletion
    • 7.4.4 Stomach Cancer
    • 7.4.5 Head and Neck Cancer
    • 7.4.6 Breast and Ovarian Cancers
    • 7.4.7 Prostate Cancer
    • 7.4.8 Cervical Cancer: NMPI79
    • 7.4.9 Uterine and Kidney Cancer: Transmembrane Protein Carbonic Anhydrase IX (CA IX)
    • 7.4.10 Colon Cancer: Serum Vascular Endothelial Growth factor (VEGF)
    • 7.4.11 Lung Cancer: Ribonucleoprotein A2/B1 and microRNA Markers
  • 7.5 Tumor Markers
    • 7.5.1 Oncology Biomarker Qualification Initiative
    • 7.5.2 CRC: Carcinoembryonic Antigen (CEA) Doubling Time
    • 7.5.3 MUC1, 2, 3 and 4
    • 7.5.4 Cytokeratins
    • 7.5.5 RAK Antigens
    • 7.5.6 Serum Amyloid A (SAA)
    • 7.5.7 Survivin
    • 7.5.8 Reg-4 Protein
    • 7.5.9 NADPH Oxidases 1 and 2 (NOX1 and NOX2)
    • 7.5.10 Prostate Secretory Protein 94- (PSP94)-Binding Protein
    • 7.5.11 Shc Proteins
    • 7.5.12 Anti-Glycan Antibodies
    • 7.5.13 YKL-40
    • 7.5.14 Alpha-Fetoprotein (AFP)-L3
    • 7.5.15 Transthyretin and Apo Lipoprotein A1 (Apo A1)
    • 7.5.16 A Disintegrin and Metalloproteinase (ADAM)
  • 7.6 Technology
    • 7.6.1 Chips
    • 7.6.2 Ettan DIGE Technology
    • 7.6.3 DNA Methylation Technology
  • 7.7 Disease-Specific Technology
    • 7.7.1 Ovarian Cancer: Bio-Rad's SELDI-Based ProteinChip
    • 7.7.2 Lung Cancer: Labeled Porphyrin Binding
    • 7.7.3 Lung Cancer: Pro-Gastrin-Releasing Peptide (ProGRP)
    • 7.7.4 Prostate Cancer: PCA3
    • 7.7.5 Bladder Cancer: ImmunoCyt/uCyt+
  • 7.8 Ultrasensitive Cancer Tests
  • 7.9 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
  • 7.10 Genetic Tests of Hereditary Cancer Risk
  • 7.11 Technical and Practical Issues for Potential New Markers
  • 7.12 Genetic Profiling
  • 7.13 Ploidy
  • 7.14 Worldwide Healthcare Spending

Appendix 1: Web Links

Appendix 2: Cancer Information Resources

Appendix 3: Colon Cancer Staging

Appendix 4: Reimbursement for Tumor Marker Testing

Appendix 5: The Pathology of Prostate Cancer

Appendix 6: Government Regulation of Tumor Marker Tests

Appendix 7: The Clinical Laboratory Improvement Act (CLIA)

Appendix 8: Marketers of Occult Blood Diagnostic Test Kits

INDEX OF FIGURES

  • Figure 1.1: Medicines in Development in Cancer
  • Figure 4.1: Bowel Cancer including Anal Cancer: Estimates: World Age-Standardized Incidence Rates per 100,000 Population, World Regions
  • Figure 4.2: Percentage of Adults Aged 50-75 Years Who Reported Being Up-to-Date with Colorectal Test Screening, by State Behavioral Risk Factor Surveillance System in the U.S., 2010
  • Figure 4.3: Progression of CRC Development
  • Figure 4.4: Prostate Cancer (C61): Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Males, World Regions
  • Figure 4.5: Prostate Cancer (C61): Estimated Incidence
  • Figure 4.6: Estimates for PCA3 Test Volume in U.S., 2005-2012
  • Figure 4.7: Pancreatic Cancer: Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Male and Females, World Regions
  • Figure 4.8: Breast Cancer: Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions
  • Figure 4.9: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer, 2013
  • Figure 4.10: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer, 2013
  • Figure 4.11: Ovarian Cancer: Estimates: European Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions
  • Figure 4.12: Cervical Cancer: Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions
  • Figure 4.13: Lung Cancer: Estimates: World Age-Standardized Incidence Rates per 100,000 Population, World Regions
  • Figure 4.14: The BTA stat Test vs. Cytology

INDEX OF TABLES

  • Table 2.1: Organ-Specific Medicines in Development for Cancer
  • Table 2.2: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2015
  • Table 2.3: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2015
  • Table 2.4: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer (Men)
  • Table 2.5: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer (Women)
  • Table 2.6: Estimated Incidence, Mortality and Prevalence Worldwide in 2012
  • Table 2.7: Cancer-Associated Genes
  • Table 2.8: Carcinogens in the Workplace
  • Table 2.9: Private Funding Levels for the Biotechnology Segment, 1995-2014
  • Table 2.10: Herceptin Worldwide Sales, 2000-2017
  • Table 2.11: Classes of Drugs Used to Treat Breast Cancer
  • Table 3.1: Tumor Biomarkers Currently in Common Use
  • Table 3.2: Global IVD Cancer Tumor Marker Testing Market Segments Growth Rates, 2011-2021
  • Table 3.3: Worldwide Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2011-2021
  • Table 3.4: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2011-2021
  • Table 3.5: Worldwide In Vitro Cancer Tumor Marker Diagnostics Market Size, 2011-2021
  • Table 3.6: U.S. In Vitro Cancer Tumor Marker Diagnostics Market Size, 2011-2021
  • Table 3.7: Japanese In Vitro Cancer Tumor Marker Diagnostics Market Size, 2011-2021
  • Table 3.8: European In Vitro Cancer Tumor Marker Diagnostics Market Size, 2011-2021
  • Table 3.9: Market Share of Major Competitors in U.S. Cancer Tumor Marker Diagnostics Market
  • Table 3.10: Major Presence in Cancer Tumor Marker Diagnostics Market
  • Table 3.11: Worldwide PSA Sales, 2011-2021
  • Table 3.12: U.S. PSA Sales, 2011-2021
  • Table 3.13: Serum Markers Used Clinically
  • Table 3.14: Drivers of IHC Growth
  • Table 3.15: Bladder Cancer Testing Efforts in the U.S. and Germany
  • Table 3.16: Worldwide Bladder Cancer Marker Sales, 2011-2021
  • Table 3.17: U.S. Bladder Cancer Marker Sales, 2011-2021
  • Table 3.18: Worldwide NMP22 Sales, 2011-2021
  • Table 3.19: Breast Cancer Products and Product Opportunities
  • Table 3.20: Products in Various Stages of Development for Cancers Other than Breast Cancer
  • Table 4.1: CRC Stages
  • Table 4.2: Colon Cancer Facts
  • Table 4.3: Number of Procedures Based on Patients Aged ≥50 Years who Reported Receiving a Fecal Occult Blood Test within One Year or a Lower Endoscopy within Ten Years, by Age and Sex in the U.S.
  • Table 4.4: Worldwide CEA Sales, 2011-2021
  • Table 4.5: U.S. CEA Sales, 2011-2021
  • Table 4.6: Japan CEA Sales, 2011-2021
  • Table 4.7: Europe CEA Sales, 2011-2021
  • Table 4.8: Rest of the World CEA Sales, 2011-2021
  • Table 4.9: Worldwide PSA Sales, 2011-2021
  • Table 4.10: U.S. PSA Sales, 2011-2021
  • Table 4.11: Japan PSA Sales, 2011-2021
  • Table 4.12: Europe PSA Sales, 2011-2021
  • Table 4.13: Rest of the World PSA Sales, 2011-2021
  • Table 4.14: Population Statistics of Serum Levels of PSA in Men Over 50 Years of Age
  • Table 4.15: Cell Doubling Time and Time to Reach PSA Level of 1,000 ng/mL
  • Table 4.16: Human tissue Kallikreins as Cancer Markers
  • Table 4.17: New Diagnostic Tests for Prostate Cancer
  • Table 4.18: Gen-Probe Genetic Testing Product Line
  • Table 4.19: Prostate Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
  • Table 4.20: Prostate Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact
  • Table 4.21: Summary of Strengths, Weaknesses, Opportunities and Threats of the Prostate Cancer Molecular Diagnostic Market
  • Table 4.22: Worldwide CA 19-9 Sales, 2011-2021
  • Table 4.23: U.S. CA 19-9 Sales, 2011-2021
  • Table 4.24: Japan CA 19-9 Sales, 2011-2021
  • Table 4.25: Europe CA 19-9 Sales, 2011-2021
  • Table 4.26: Rest of the World CA 19-9 Sales, 2011-2021
  • Table 4.27: CA 19-9 Levels in Management of Pancreatic Cancer
  • Table 4.28: Worldwide CA 15-3 Sales, 2011-2021
  • Table 4.29: U.S. CA 15-3 Sales, 2011-2021
  • Table 4.30: Japan CA 15-3 Sales, 2011-2021
  • Table 4.31: Europe CA 15-3 Sales, 2011-2021
  • Table 4.32: Rest of the World CA 15-3 Sales, 2011-2021
  • Table 4.33: TPA Marker Sensitivity
  • Table 4.34: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: How to Interpret Test Results
  • Table 4.35: Worldwide CA-125 Sales, 2011-2021
  • Table 4.36: U.S. CA-125 Sales, 2011-2021
  • Table 4.37: Japan CA-125 Sales, 2011-2021
  • Table 4.38: Europe CA-125 Sales, 2011-2021
  • Table 4.39: Rest of the World CA-125 Sales, 2011-2021
  • Table 4.40: Worldwide HVP Sales, 2011-2021
  • Table 4.41: U.S. HPV Sales, 2011-2021
  • Table 4.42: Japan HVP Sales, 2011-2021
  • Table 4.43: Europe HVP Sales, 2011-2021
  • Table 4.44: Rest of the World HVP Sales, 2011-2021
  • Table 4.45: HCPCS Codes for Screening Pap Tests
  • Table 4.46: HCPCS Codes for Screening Pap Tests Rate
  • Table 4.47: Number of Pap Smears Performed by Country
  • Table 4.48: Lung Cancer Survival Rates
  • Table 4.49: American Cancer Society Lung Cancer Facts
  • Table 4.50: Predictive and Prognostic Rates
  • Table 4.51: Tests Identifying Molecular Markers in Urine
  • Table 4.52: Worldwide NMP22/BTA Sales, 2011-2021
  • Table 4.53: U.S. NMP22/BTA Sales, 2011-2021
  • Table 4.54: Japan NMP22/BTA Sales, 2011-2021
  • Table 4.55: Europe NMP22/BTA Sales, 2011-2021
  • Table 4.56: Rest of the World NMP22/BTA Sales, 2011-2021
  • Table 4.57: Patient Category Applications
  • Table 4.58: Worldwide Alpha-Fetal Protein (AFP) Sales, 2011-2021
  • Table 4.59: U.S. Alpha-Fetal Protein (AFP) Sales, 2011-2021
  • Table 4.60: Japan Alpha-Fetal Protein (AFP) Sales, 2011-2021
  • Table 4.61: Europe Alpha-Fetal Protein (AFP) Sales, 2011-2021
  • Table 4.62: Rest of the World Alpha-Fetal Protein (AFP) Sales, 2011-2021
  • Table 4.63: Key Oncology Diagnostic Tests, Roche, 2015
  • Table 4.64: Potential Uses of Molecular Diagnostics in Cancer Management
  • Table 4.65: Markers Frequently Used to Identify Adult Stem Cells in the Prostate, Breast and Intestine
  • Table 4.66: MammaPrint: Key Features
  • Table 5.1: Tumor Diagnosis Immunoassays
  • Table 5.2: Tumor Diagnosis Radioimmunoassays
  • Table 6.1: List and Discounted Prices for Abbott Tumor Marker Tests
  • Table 7.1: Categories of Oncogenes
  • Table 7.2: Familial Cancer Syndromes and Tumor Suppressor Genes
  • Table A7.1: Financial Comparison for Moderate and Waived CLIA Labs
  • Table A8.1: List of Marketers of Fecal Occult Blood Diagnostic Test Kits
Back to Top